Man looking up
Woman looking up
Woman looking up

Itch Relief

Significant improvement in the severity of itch

 

~68% of patients achieved WI-NRS Success at Week 81,2*

35%49%†67%†19%23%26%ZORYVE(n=218)Vehicle(n=115)WEEK 2WEEK 4WEEK 8DERMIS-1
42%‡56%†69%†21%22%33%ZORYVE(n=229)Vehicle(n=116)WEEK 2WEEK 4WEEK 8DERMIS-2
35%49%†67%†42%‡56%†69%†19%23%26%21%22%33%†P<0.0001 vs vehicle.‡P<0.001 vs vehicle.ZORYVE(n=218)Vehicle(n=115)ZORYVE(n=229)Vehicle(n=116)WEEK 2WEEK 4WEEK 8WEEK 2WEEK 4WEEK 8DERMIS-1DERMIS-2

†P<0.0001 vs vehicle.
‡P<0.001 vs vehicle.

*WI-NRS Success defined as a ≥4-point improvement for patients with a baseline score ≥4.
WI-NRS scale: 0 (no itch) to 10 (worst imaginable itch).

 

In a Phase 2 study

Itch-related sleep loss improved while on active treatment8§

§Based on patient-reported outcomes (PROs) data related to itch from a Phase 2b study evaluating efficacy and safety of once-daily roflumilast cream compared to vehicle for plaque psoriasis for 12 weeks. Patients were evaluated on itch-related sleep loss (IRSL) by answering a numeric scale 0 (no IRSL) to 10 (IRSL as bad as it could be) over the previous 24 hours.

Did you know?Did you know?

ITCH IS THE MOST BOTHERSOME and frequently reported symptom of psoriasis, according to a 2012 population-based survey of over 2,700 patients with plaque psoriasis in North America and Europe.9

Study Design
See Before & After
View Safety Profile